/
KYMR
$109.32+$1.20 (+1.11%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$8.9B
82M shares
52-week range
$36.65 – $130.05
78% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$53.25
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.9M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Cost of revenue | $205.0K | $825.0K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$205.0K | $2.1M | $34.0M | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M |
| Gross margin | — | 71.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $17.7M | $37.2M | $62.1M | $137.0M | $164.2M | $189.1M | $240.2M | $316.6M |
| Operating income | −$21.5M | −$42.2M | −$46.3M | −$100.5M | −$161.3M | −$165.5M | −$261.6M | −$349.4M |
| EBITDA | −$21.2M | −$40.4M | −$43.7M | −$97.6M | −$151.7M | −$143.2M | −$216.2M | −$303.1M |
| Net income | −$21.5M | −$41.3M | −$45.6M | −$100.2M | −$154.8M | −$147.0M | −$223.9M | −$311.4M |
| Net margin | — | -1407.4% | -134.0% | -137.6% | -330.6% | -187.0% | -475.6% | -794.4% |
| EPS (diluted) | -0.48 | -0.93 | -0.99 | -2.09 | -2.87 | -2.52 | -2.98 | -3.69 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $84M | $-3.48 | $-3.99–$-2.80 | 16 |
| 2027 | $43M | $-4.29 | $-5.07–$-3.26 | 16 |
| 2028 | $41M | $-4.68 | $-7.75–$-3.40 | 14 |
| 2029 | $68M | $-4.63 | $-7.80–$-0.78 | 8 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.11
Price
$109.32
Implied downside
-100%
Peer comparison
Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
www.kymeratx.com- Employees
- 253
- IPO / List date
- Aug 21, 2020
- HQ
- WATERTOWN, MA
Held by traders on TradeandTell
No one on the platform currently holds KYMR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-06-30 | 143,093 | $4.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded KYMR yet.
